By Counterforce Health Team in Naglazyme (galsulfase) —

How to Get Naglazyme (Galsulfase) Covered by Cigna in Texas: Complete Prior Authorization and Appeals Guide

Answer Box: Getting Naglazyme (Galsulfase) Covered by Cigna in Texas

Fast Path: Naglazyme requires prior authorization from Cigna. Submit via CoverMyMeds portal or Cigna provider portal with confirmed MPS VI diagnosis, enzyme/genetic testing, and medical necessity letter. If denied, file internal appeal within 180 days, then Texas Independent Review Organization (IRO) external review within 4 months. First step today: Have your doctor initiate prior authorization with complete diagnostic documentation and treatment history.

Table of Contents

  1. When Naglazyme Alternatives Make Sense
  2. Understanding Your Options: No True Alternatives Exist
  3. Pros and Cons of Available Approaches
  4. Exception Strategy: Building Your Case
  5. Coordination with Your Healthcare Team
  6. Re-trying for Naglazyme Later
  7. Appeals Process in Texas
  8. FAQ

When Naglazyme Alternatives Make Sense

For MPS VI (mucopolysaccharidosis type 6), the reality is stark: Naglazyme (galsulfase) is the only FDA-approved enzyme replacement therapy available. Unlike other rare diseases where multiple treatment options exist, Cigna's coverage policy explicitly states there are no formulary alternatives to galsulfase for MPS VI treatment.

However, understanding when to pursue different approaches can help you navigate coverage challenges:

When to Consider Alternative Strategies:

  • Initial prior authorization denial
  • Severe infusion reactions to Naglazyme
  • Insurance formulary restrictions
  • Geographic access limitations
  • Cost-sharing concerns

Coverage Reality Check: Cigna requires prior authorization for Naglazyme with strict criteria including confirmed diagnosis via enzyme assay or genetic testing, documented disease severity, and specialist oversight.

Understanding Your Options: No True Alternatives Exist

Enzyme Replacement Therapy

Naglazyme (galsulfase) remains the singular option for enzyme replacement in MPS VI. The FDA labeling specifies it as recombinant human N-acetylgalactosamine 4-sulfatase for patients with confirmed MPS VI.

Key Requirements for Coverage:

  • Confirmed MPS VI diagnosis
  • Enzyme deficiency or genetic testing results
  • Specialist consultation (genetics/metabolism)
  • Baseline functional assessments
  • Weight-based dosing at 1 mg/kg weekly

Non-ERT Management Approaches

When Naglazyme isn't immediately accessible, supportive care becomes crucial:

Symptomatic Management:

  • Orthopedic interventions for skeletal complications
  • Respiratory support and monitoring
  • Cardiac evaluation and management
  • Physical and occupational therapy
  • Pain management protocols

Investigational Options:

  • Gene therapy clinical trials (research phase only)
  • Hematopoietic stem cell transplantation (limited use, high risk)
Note: These approaches don't replace enzyme therapy but can help manage symptoms while pursuing coverage.

Pros and Cons of Available Approaches

Naglazyme (Standard ERT)

Pros:

  • Only disease-modifying treatment for MPS VI
  • Proven efficacy in clinical trials
  • Established safety profile
  • Specialist center support networks

Cons:

  • Requires prior authorization
  • High cost ($600K-$1.8M+ annually)
  • Weekly IV infusions
  • Risk of infusion reactions
  • No CNS penetration

Supportive Care Only

Pros:

  • Typically covered by insurance
  • Addresses immediate symptoms
  • Lower risk profile
  • Can improve quality of life

Cons:

  • No disease modification
  • Progressive deterioration continues
  • Multiple specialist coordination needed
  • Symptomatic relief only

Access Considerations: Counterforce Health helps patients navigate complex prior authorization requirements by turning insurance denials into targeted, evidence-backed appeals that align with payer policies and clinical guidelines.

Exception Strategy: Building Your Case

Medical Necessity Documentation

Your physician must demonstrate that Naglazyme is medically necessary by including:

Required Clinical Elements:

  • Confirmed MPS VI diagnosis with enzyme levels or genetic testing
  • Baseline functional assessments (6-minute walk test, pulmonary function)
  • Documentation of disease progression
  • Treatment goals and expected outcomes
  • Monitoring plan

Supporting Evidence

Guideline Citations to Include:

  • FDA prescribing information
  • International MPS consensus statements
  • Peer-reviewed efficacy studies
  • Specialty society recommendations

Documentation Checklist:

  • Diagnostic test results
  • Specialist consultation notes
  • Baseline functional measurements
  • Treatment history (if any)
  • Family history and genetic counseling
  • Infusion center arrangements

Formulary Exception Request

If Naglazyme is non-formulary on your specific Cigna plan, request an exception using Cigna's formulary exception process:

Required Elements:

  • Clinical rationale for non-formulary drug
  • Documentation that no formulary alternatives exist for MPS VI
  • Cost-effectiveness analysis if requested
  • Prescriber attestation of medical necessity

Coordination with Your Healthcare Team

Prescriber Responsibilities

Your metabolic specialist or geneticist should:

  1. Submit comprehensive prior authorization with all required documentation
  2. Coordinate with infusion center for administration logistics
  3. Provide ongoing monitoring and outcome assessments
  4. Document clinical response for continuation approvals

Pharmacy Coordination

Specialty Pharmacy Requirements:

  • Cigna typically uses Express Scripts/Accredo for specialty drugs
  • Confirm network status before prescription submission
  • Verify prior authorization completion
  • Schedule delivery and infusion logistics

Patient/Family Role

Your Action Items:

  • Gather insurance information and policy details
  • Coordinate appointments for baseline assessments
  • Maintain communication between all providers
  • Track prior authorization status
  • Prepare for potential appeals
From our advocates: "We've seen families succeed by creating a shared document with all providers listing required tests, timelines, and who's responsible for each piece. This prevents delays when Cigna requests additional information during review."

Re-trying for Naglazyme Later

What to Document During Alternative Treatment

If you must pursue supportive care while appealing coverage:

Clinical Documentation:

  • Detailed symptom progression
  • Functional decline measurements
  • Quality of life impacts
  • Healthcare utilization increases
  • Complications from untreated MPS VI

Timing Your Re-application

Optimal Timing:

  • After completing internal appeals process
  • When new clinical evidence emerges
  • Following policy changes or updates
  • After establishing specialist care relationship

Strengthening Your Case

Additional Evidence to Gather:

  • Peer-reviewed studies supporting early intervention
  • Economic analyses of ERT vs. supportive care costs
  • Letters from multiple specialists
  • Patient/family impact statements

Appeals Process in Texas

Internal Appeals with Cigna

Timeline: File within 180 days of denial

Standard Review: 30 days for pre-service determinations Expedited Review: 72 hours for urgent cases

Required Documentation:

  • Original denial letter
  • Additional medical records
  • Updated physician letter
  • Clinical literature supporting necessity

Texas Independent Review Organization (IRO)

If Cigna denies your internal appeal, Texas law provides external review rights:

Timeline: File within 4 months of final internal denial

Standard IRO Review: 20 days for pre-authorization cases Expedited IRO Review: 3 days for life-threatening situations

How to File:

  1. Complete TDI Form LHL712
  2. Attach final Cigna denial letter
  3. Include all medical records and supporting documentation
  4. Submit to assigned IRO (Cigna provides contact information)

IRO Decision: Binding on Cigna - if overturned, coverage must be provided

Getting Help in Texas

Texas Department of Insurance: 1-800-252-3439 Office of Public Insurance Counsel: 1-877-611-6742 IRO Information Line: 1-866-554-4926

Counterforce Health specializes in transforming insurance denials into successful appeals by identifying specific denial reasons and crafting point-by-point rebuttals aligned with payer policies and clinical evidence.

Coverage at a Glance

Requirement What It Means Where to Find It Source
Prior Authorization Required before coverage Cigna provider portal Coverage Policy
Confirmed Diagnosis MPS VI via enzyme/genetic testing Lab results, genetic counselor FDA Label
Specialist Oversight Genetics or metabolism physician Provider credentials Cigna Policy
Internal Appeal Deadline 180 days from denial Denial letter Cigna Appeals
External Review Deadline 4 months from final denial TDI guidance Texas IRO Process

FAQ

How long does Cigna prior authorization take for Naglazyme in Texas? Standard prior authorization decisions are made within 72 hours for non-urgent requests. Expedited reviews for urgent cases are completed within 24 hours.

What if Naglazyme is non-formulary on my Cigna plan? Submit a formulary exception request demonstrating medical necessity and that no formulary alternatives exist for MPS VI. Include comprehensive clinical documentation supporting the need for enzyme replacement therapy.

Can I request an expedited appeal if my condition is worsening? Yes. Texas allows expedited internal appeals (72 hours) and expedited IRO external review (3 days) when delays could seriously jeopardize your health or ability to regain maximum function.

Does step therapy apply to Naglazyme? No. Since Naglazyme is the only FDA-approved enzyme replacement therapy for MPS VI, step therapy requirements don't typically apply. However, Cigna may require documentation of disease severity and specialist consultation.

What happens if the IRO overturns Cigna's denial? The IRO decision is binding. Cigna must provide coverage for Naglazyme according to the IRO's determination. This includes retroactive coverage if applicable.

How much does Naglazyme cost without insurance? Annual costs range from approximately $600,000 to $1.8 million+ depending on patient weight, as dosing is 1 mg/kg weekly. Actual costs vary based on negotiated rates and patient assistance programs.

Can I get help with the appeals process? Yes. Contact the Texas Department of Insurance (1-800-252-3439), Office of Public Insurance Counsel (1-877-611-6742), or organizations like Disability Rights Texas. Professional appeal assistance services are also available.

What if I've already started Naglazyme and Cigna wants to stop coverage? File an immediate appeal and request expedited review. Document any clinical improvement or stabilization since starting therapy. Include updated functional assessments and physician letters supporting continued medical necessity.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Insurance coverage decisions depend on individual policy terms and clinical circumstances. Always consult with your healthcare providers and insurance representatives for guidance specific to your situation. For assistance with Texas insurance regulations, contact the Texas Department of Insurance at 1-800-252-3439.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.